Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
3.940
-0.070 (-1.75%)
At close: Dec 5, 2025, 4:00 PM EST
3.990
+0.050 (1.27%)
After-hours: Dec 5, 2025, 7:38 PM EST
Evolent Health Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Evolent Health stock have an average target of 12.25, with a low estimate of 7.00 and a high estimate of 18. The average target predicts an increase of 210.91% from the current stock price of 3.94.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Evolent Health stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Buy | 7 | 7 | 7 | 7 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 15 | 15 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $12 → $9.5 | Strong Buy | Maintains | $12 → $9.5 | +141.12% | Nov 21, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $13 → $7 | Buy | Maintains | $13 → $7 | +77.66% | Nov 17, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $16 → $9 | Strong Buy | Maintains | $16 → $9 | +128.43% | Nov 14, 2025 |
| BMO Capital | BMO Capital | Buy Initiates $7 | Buy | Initiates | $7 | +77.66% | Nov 13, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $18 → $12 | Buy | Maintains | $18 → $12 | +204.57% | Nov 12, 2025 |
Financial Forecast
Revenue This Year
1.90B
from 2.55B
Decreased by -25.82%
Revenue Next Year
2.44B
from 1.90B
Increased by 28.55%
EPS This Year
0.09
from -0.81
EPS Next Year
0.35
from 0.09
Increased by 272.35%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.0B | 2.6B | ||||
| Avg | 1.9B | 2.4B | ||||
| Low | 1.8B | 2.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -22.3% | 39.7% | ||||
| Avg | -25.8% | 28.5% | ||||
| Low | -28.6% | 12.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.36 | 0.82 | |||
| Avg | 0.09 | 0.35 | |||
| Low | 0.01 | 0.17 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 765.0% | |||
| Avg | - | 272.4% | |||
| Low | - | 75.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.